[2-chloro-5-(2-methoxyethyl)phenyl]methanol | 1251530-47-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [2-chloro-5-(2-methoxyethyl)phenyl]methanol
• 英文别名: [2-Chloro-5-(2-methoxyethyl)phenyl]methanol
• CAS: 1251530-47-8
• 化学式: C₁₀H₁₃ClO₂
• 分子量: 200.665
• InChiKey: FYKROOIEQPZMHT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  [2-chloro-5-(2-methoxyethyl)phenyl]methanol 在 咪唑 、 碘 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 以77%的产率得到1-chloro-2-(iodomethyl)-4-(2-methoxyethyl)benzene
  参考文献：
  名称：

  Addressing time-dependent CYP 3A4 inhibition observed in a novel series of substituted amino propanamide renin inhibitors, a case study

  摘要：

  Time-dependent inhibitors of CYPs have the potential to perpetrate drug-drug interactions in the clinical setting. After finding that several leading compounds in a novel series of substituted amino propanamide renin inhibitors inactivated CYP3A4 in an NADPH-dependent and time-dependent manner, a search to identify the cause of this liability was initiated. Extensive SAR revealed that the amide bridge present in compound 1 as a possible culprit. Through the installation of a metabolic soft spot distal to this moiety, potent renin inhibitors with improved CYP profile were identified. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.030
• 作为产物：
  描述：

  在 二异丁基氢化铝 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 16.0h， 生成 [2-chloro-5-(2-methoxyethyl)phenyl]methanol
  参考文献：
  名称：

  Addressing time-dependent CYP 3A4 inhibition observed in a novel series of substituted amino propanamide renin inhibitors, a case study

  摘要：

  Time-dependent inhibitors of CYPs have the potential to perpetrate drug-drug interactions in the clinical setting. After finding that several leading compounds in a novel series of substituted amino propanamide renin inhibitors inactivated CYP3A4 in an NADPH-dependent and time-dependent manner, a search to identify the cause of this liability was initiated. Extensive SAR revealed that the amide bridge present in compound 1 as a possible culprit. Through the installation of a metabolic soft spot distal to this moiety, potent renin inhibitors with improved CYP profile were identified. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.030

文献信息

• Renin Inhibitors
  申请人：Bayly Christopher I.

  公开号：US20090281103A1

  公开（公告）日：2009-11-12

  The present invention relates to novel renin inhibitors of the general Formula (I), and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds. These novel renin inhibitors are used in treating cardiovascular events and renal insufficiency.

  本发明涉及一种新型肾素抑制剂，其通式为（I），并且它们作为制备制药组合物的活性成分使用。该发明还涉及相关方面，包括化合物的制备过程。这些新型肾素抑制剂用于治疗心血管事件和肾功能不全。
• RENIN INHIBITORS
  申请人：BAYLY CHRISTOPHER I.

  公开号：US20120046293A1

  公开（公告）日：2012-02-23

  The present invention relates to renin inhibitor compounds having the structure and their use in treating cardiovascular events and renal insufficiency.

  本发明涉及具有以下结构的肾素抑制剂化合物及其在治疗心血管事件和肾功能不全中的应用。
• Renin inhibitors
  申请人：Merck Canada Inc.

  公开号：US08063105B2

  公开（公告）日：2011-11-22

  The present invention relates to novel renin inhibitors of the general Formula (I), and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds. These novel renin inhibitors are used in treating cardiovascular events and renal insufficiency.

  本发明涉及一种新型肾素抑制剂，其通式为（I），以及它们作为制备药物组合物中的活性成分的用途。本发明还涉及相关方面，包括化合物的制备过程。这些新型肾素抑制剂用于治疗心血管事件和肾功能不全。
• WO2007/9250
  申请人：——

  公开号：——

  公开（公告）日：——
• US8063105B2
  申请人：——

  公开号：US8063105B2

  公开（公告）日：2011-11-22